TEVA
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
Article Summary
HOLD- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026 at 7:00 a.m.
- ET, followed by a conference call and live webcast at 8:00 A.M.
- Teva- Pharmaceutical Industries Ltd.
- ADR is transforming into a leading innovative biopharmaceutical company enabled by a world-class generics business, with its commitment to bettering health having never wavered over 120 years.
- Teva is innovating in the fields of neuroscience and immunology to provide complex generic medicines, biosimilars and pharmacy brands worldwide.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 5.8% | 25% | 35.0 ptsBelow Screener (5.8%) - Weak growth |
| EPS Growth Next 5Y ? | 5.5% | 25% | 20.0 ptsWeak (5.5%) - Low expectations |
| Target Price Upside ? | 32.6% | 20% | 85.0 ptsLarge Upside (32.6%) - Target: $41.75 vs Current: $31.48 |
| Gross Margin % ? | 52.2% | 15% | 80.0 ptsVery Healthy (52.2%) - High-quality margins |
| Drawdown from 52-Wk High ? | -15.7% | 15% | 40.0 ptsMild Pullback (-15.7%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About TEVA
- Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
- It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
- The company also focuses on the central nervous system (CNS), respiratory, and oncology areas.
- It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.
- The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders – chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder.
- The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.
- It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH.
- The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.